A recent study reveals that people who stop using blockbuster weight-loss injections like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who halt conventional diet and exercise programs.
Research printed in a leading medical journal points out that while overweight people frequently drop about a fifth of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People using such medications must be aware of the potential of rapid weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight within about one and a half years.
Comparing Therapies
The research, which reviewed 37 of studies involving thousands of participants, compared the results of the injectable medications with older methods.
Researchers note that people who lose weight through diet and exercise usually experience a slower weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Nutrition scientists suggest the way of the injections accounts for the accelerated weight return.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
Professionals contend that, given the likelihood of relapse, the therapy is often ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the chronic character of excess weight," similar to managing diseases like hypertension.
User Testimonies
Users who have discontinued the jabs report a powerful return of hunger.
"It was like something flipping and I was suddenly ravenous," described a patient.
This challenge is compounded if users have not established lasting dietary or behavioural changes during therapy.
Widespread Use
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while these medications are potent tools for weight loss, they are not a standalone solution and maintained weight loss likely depends on ongoing lifestyle management.
